GlobeNewswire

Better understanding of nature needed to steer us away from too hot Earth

Del

Tilting the climate to a “hothouse Earth” state can only be prevented if we understand how the Earth is breathing, states ICOS, the Integrated Carbon Observation System.  Standardised long-term observations on how greenhouse gases circulate between land, air and sea increase our knowledge on how carbon pollution and nature’s processes influence the climate change. This is crucial when deciding on actions to slow down the global warming. 

HELSINKI, Finland, Sept. 04, 2018 (GLOBE NEWSWIRE) -- A group of leading scientists warn in a recently published article that the combined consequences of 10 already ongoing climate change processes could cause a domino effect and lock the Earth in an extremely hot state, “hothouse”. Examples of such processes are loss of sea-ice, dying of boreal forests and permafrost thawing. The scientists argue that once a certain threshold is crossed, stabilising the Earth we know today might not be possible anymore regardless of our actions.

Many of these 10 climate change processes are linked to the way carbon circulates between land, air and sea. They all also have tipping points that once passed, lead the Earth into a new irreversible state. There might even be more of such tipping points than what the scientists have found so far. To understand the ongoing processes and to recognize new ones, a comprehensive Earth observation system is needed

We need standardised observations across the countries and even continents

“We need data from observations to understand the complex processes behind these tipping points. Since greenhouse gases drive climate change, it is critical to understand how these gases circulate, what produces them and what reduces their amounts in the atmosphere. Key to this understanding are observations, which follow the highest standards, span over tens of years and across the countries and even continents. Well organised research frameworks ensure that scientists and societies have this data at their disposal,” says Dr. Werner Kutsch, Director General of ICOS Integrated Carbon Observation System.

ICOS facilitates greenhouse gas measurements in Europe, where 12 participating countries have jointly built a network of over 130 stations observing greenhouse gases across the continent. ICOS data provides a comprehensive view on the greenhouse gases produced by humans, but also of their natural sources and sinks.

“A comprehensive view is crucial since, in the end, the atmosphere is integrating everything. This study alarms us, but also confirms that we are on the right track to observe natural ecosystems as well as human pollution. Being unique in uniting atmospheric, ecosystem and ocean observations, ICOS confirms the European leadership in greenhouse gas observations,” states Dr. Kutsch. 

Dr. Kutsch is therefore looking forward to the 3rd ICOS Science Conference held in September in Prague, Czech Republic, where leading scientists of the greenhouse gas research field from all over the world will meet. Besides purely scientific and technical topics, the attendees will also discuss how we can close the gap between science and policy-makers to ensure the Earth is steered away from a potential threshold before it is too late.

Caption texts for the pictures:
Forests are greenhouse gas sinks, and measurements of the carbon circulation between the air and land are carried out with equipment placed high on towers above forests.  Dr. Bart Kruijt at the ICOS station in Loobos, The Netherlands.

For more information

Dr. Werner Kutsch, Director General
ICOS, Integrated Carbon Observation System
Phone: +358 50 4484598
Email: werner.kutsch@icos-ri.eu

Katri Ahlgren, Head of Communications
ICOS, Integrated Carbon Observation System
Phone: +358 40 3502557
Email: katri.ahlgren@icos-ri.eu

Press Accreditation to the ICOS Science Conference, Sep 11-14, in Prague:
Please contact Katri Ahlgren, details above.

The Integrated Carbon Observation System, ICOS, is a European-wide greenhouse gas research infrastructure.  ICOS produces standardised data on greenhouse gas concentrations in the atmosphere, as well as on carbon carbon circulation between the atmosphere, the earth and oceans. This information is being used by scientists as well as by decision makers for predicting and mitigating climate change. The ICOS data is based on the measurements from 134 stations across 12 European countries. The international organization is financed by its member countries. 
Webpage: www.icos-ri.eu  Twitter: https://twitter.com/icos_ri

ICOS Science Conference held September 11-14, in Prague Czech Republic. The ICOS conference gathers more than 300 scientists to discuss the scientific topics around greenhouse gas measurement and climate change. The themes of the conference vary from purely scientific sessions to ones related to the Paris Agreement and other policy making.  www.icos-ri.eu/science-conference

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/66763ae9-8a80-41ab-a2ea-978b36c02863

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®16.6.2019 18:00:00 CESTPressemelding

CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, will host a conference call and webcast tomorrow morning, June 17, 2019, at 8:00 AM ET. Management looks forward to reviewing top-line data from PROTECT, one of two pivotal Phase 3 studies for Sci-B-Vac®, the company’s trivalent hepatitis B vaccine. Conference Call and Webcast Details The live webcast and slide presentation can be accessed via the Events/Presentations page in the investors section of the company’s website, https://www.vbivaccines.com/investors/events-presentations/, or by clicking this link: https://edge.media-server.com/m6/p/7ryhzgu2. A replay of the webcast will be archived on the company’s website for 90 days following the live conference call. To listen to the live conference call, please dial: - Toll-free U.S. & Canada Dial-In: (866) 602-1050 - Internat

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad